Compare MSS & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MSS | VYNE |
|---|---|---|
| Founded | 2019 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4M | 12.5M |
| IPO Year | 2023 | 2018 |
| Metric | MSS | VYNE |
|---|---|---|
| Price | $0.36 | $0.59 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $4.25 | N/A |
| AVG Volume (30 Days) | 1.1M | ★ 14.9M |
| Earning Date | 12-22-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $121,477,295.00 | $524,000.00 |
| Revenue This Year | $4.08 | N/A |
| Revenue Next Year | $7.89 | $16.67 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 37.96 | 6.29 |
| 52 Week Low | $0.30 | $0.28 |
| 52 Week High | $3.96 | $4.30 |
| Indicator | MSS | VYNE |
|---|---|---|
| Relative Strength Index (RSI) | 34.31 | 71.15 |
| Support Level | $0.30 | $0.56 |
| Resistance Level | $0.56 | $0.75 |
| Average True Range (ATR) | 0.06 | 0.05 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 21.01 | 57.48 |
Maison Solutions Inc is a fast-growing, specialty grocery retailer offering traditional Asian food and merchandise to modern U.S. consumers, particularly members of Asian-American communities. It is committed to providing Asian fresh produce, meat, seafood, and other daily necessities in a manner that caters to traditional Asian-American family values and cultural norms, while also accounting for the new and faster-paced lifestyle of younger generations and the diverse communities in which it operates. The company's merchandise includes fresh and, meats, seafood, and other groceries that are not found in mainstream supermarkets, including a variety of Asian vegetables and fruits such as broccoli, bitter melon, winter gourd, Shanghai baby bok choy, longan, and lychee.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.